Efficacy and safety of tiotropium bromide in chronic obstructive pulmonary disease a systematic review of randomized clinical trials
Main Article Content
Resumo
Chronic obstructive pulmonary disease (COPD) is among the most prevalent pulmonary diseases. This study aimed at assessing the efficacy and safety of anticholinergic tiotropium bromide (TB) in Chronic obstructive pulmonary disease patients. This is a systematic review of randomized clinical trials performed in the Brazilian Cochrane Center. Electronic database searched: Cochrane library, Medline, LILACS, Pubmed. There were no language, date or other restrictions. Participants: Patients with Chronic obstructive pulmonary disease. Intervention: tiotropium bromide. Comparison: Other bronchodilators or placebo. Outcomes: Mortality, Chronic obstructive pulmonary disease exacerbation, hospitalizations, adverse effects. Results: 14 studies were included in this systematic review. Mortality was lower in the tiotropium bromide group when compared with the salmeterol group [statistical significance: relative risk (RR) 0.16, confidence interval 95% (CI) 0.03 to 0.89, number needed to treat (NNT) of 100]. There was not a statistical difference in the mortality outcome in the comparison between tiotropium bromide and placebo groups (RR 0.88, CI 0.74 to 1.06). Chronic obstructive pulmonary disease exacerbation decreases significantly in the tiotropium bromide group when compared to placebo (statistical significance: RR 0.85, CI 0.77 to 0.93, NNT 25), but in comparison to the salmeterol group there was no statistical difference (RR 0.93, CI 0.80 to 1.08). The number of hospitalizations was lower in the tiotropium bromide group than in the placebo group (statistical significance: RR 0.77, CI 0.59 to 0.99, NNT 50). The results indicate that tiotropium bromide is an effective once-daily bronchodilator. Tiotropium bromide was associated with consistent health benefits, including reduced chronic obstructive pulmonary disease exacerbations, hospitalizations and even mortality when compared with salmeterol.
Article Details
Declaração de Direito Autoral
Eu (nome do autor responsável) _______________________________________________ declaro que o presente artigo intitulado ___________________________________é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade. Declaro, ainda, que uma vez publicado na revista Revista da Sociedade Brasileira de Clinica Médica, editada pela Sociedade Brasileira de Clínica Médica, o mesmo jamais será submetido por um dos demais co-autores a qualquer outro meio de divulgação científica impressa ou eletrônica.
Por meio deste instrumento, em meu nome e dos demais co-autores, cedo os direitos autorais do referido artigo à Revista da Sociedade Brasileira de Clinica Médica, e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (n 9610 19 de fevereiro de 1998) que altera, atualiza e consolida a legislação sobre direitos autorais e dá outras providências. Disponível em: http://www.planalto.gov.br/ccivil_03/leis/l9610.htm
_________________________ |
___________________ |
Local, data |
Assinatura |
SOCIEDADE BRASILEIRA DE CLÍNICA MÉDICA
CNPJ/MF 062.279.617/0001-45
Rua Botucatu, nº 572, cj. 112, São Paulo, SP
Download da Declaração de Direito Autoral.